Harrow (HROW) Gains from Investment Securities (2010 - 2025)
Harrow (HROW) recorded quarterly Gains from Investment Securities of $8.7 million in Q4 2025, up 6227.84% quarter-over-quarter from $136745.0 in Q3 2025, and up 128.85% on a YoY basis from $3.8 million in Q4 2024.
Harrow (HROW) Gains from Investment Securities (2010 - 2025) Analysis & Trends
Harrow's Gains from Investment Securities history runs 15 years deep, the most recent figure standing at $8.7 million for Q4 2025.
- In Q4 2025, Gains from Investment Securities rose 128.85% year-over-year to $8.7 million; the TTM figure through Dec 2025 stood at $12.8 million (up 142.89% YoY), while the FY2025 annual figure was $126544.0, down 94.87% from the prior year.
- Gains from Investment Securities was $8.7 million for Q4 2025 at Harrow, up from $136745.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $41.2 million in Q3 2021 to a low of -$1.7 million in Q4 2021.
- Historically, Gains from Investment Securities has averaged $2.7 million across 5 years, with a median of $57130.0 in 2023.
- The sharpest annual moves came in 2021 and 2023: Gains from Investment Securities soared 5493100.0% in 2021, then tumbled 1105.26% in 2023.
- A 5-year view of Gains from Investment Securities shows it stood at -$1.7 million in 2021, then soared by 96.74% to -$57000.0 in 2022, then sank by 1105.26% to -$687000.0 in 2023, then surged by 650.36% to $3.8 million in 2024, then jumped by 128.85% to $8.7 million in 2025.
- The last three Gains from Investment Securities figures came in at $8.7 million (Q4 2025), $136745.0 (Q3 2025), and $5566.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | Harrow | 1.34 Bn | 1.24 Bn | 27.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.65 Mn |
| Dec 31, 2025 | 8.65 Mn |
| Sep 30, 2025 | 136,745.00 |
| Sep 30, 2025 | 136,745.00 |
| Jun 30, 2025 | 5,566.00 |
| Jun 30, 2025 | 5,566.00 |
| Mar 31, 2025 | 38,000.00 |
| Mar 31, 2025 | 38,000.00 |
| Dec 31, 2024 | 3.78 Mn |
| Dec 31, 2024 | 3.78 Mn |
| Sep 30, 2024 | 59,836.00 |
| Sep 30, 2024 | 59,836.00 |
| Jun 30, 2024 | 59,836.00 |
| Jun 30, 2024 | 59,836.00 |
| Mar 31, 2024 | 377,000.00 |
| Mar 31, 2024 | 377,000.00 |
| Dec 31, 2023 | -687,000.00 |
| Dec 31, 2023 | -687,000.00 |
| Sep 30, 2023 | 54,424.00 |
| Sep 30, 2023 | 54,424.00 |